Drug Delivery Systems - Articles and news items


Injectable drug delivery market worth US$624.50 billion by 2021

Industry news / 23 March 2017 / Niamh Marriott, Junior Editor

According to a new report, the global injectable drug delivery market is projected to reach US$624.50 Billion by 2021 from US$362.38 billion in 2016…

Quotient Clinical

Quotient Clinical hosts formulation development and drug delivery seminar series

Supplier news / 15 June 2016 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® company, is holding a series of formulation development and drug delivery seminars this June and July…

Quotient Clinical

Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs

Supplier news / 4 May 2016 / Quotient Clinical

Quotient Clinical and Upperton have announced a partnership to address drug delivery challenges…

Stem cell nano drug delivery applications to treat diabetes

Stem cell nano drug delivery applications to treat diabetes

Drug Delivery, Issue 2 2016 / 4 May 2016 / Vishal Shahidadpury, Anjali Hirani and Yashwant Pathak - University of South Florida Health

Stem cell therapy is currently utilised in medicine for its application in tissue repair and regenerative medicine. Unique characteristics of stem cells, such as self-renewal and differentiation, allow its function to be applicable for therapeutic purposes. Nanotechnology and cell microencapsulation have been researched and used as a means to protect cells from innate immune responses while permitting targeted drug delivery, as well as for sustained release of therapeutic agents to specific organs or cells. This review will provide an overview of stem cells, the purpose of nanotechnology and various surface modifications of nanoparticles for enhanced drug delivery, as well as describe how stem cell therapy is used for type 1 and type 2 diabetes mellitus. Additionally, a specific application of nanoparticle encapsulation and human embryonic stem cells in achieving glycaemic control, as seen in type 1 diabetes-induced immune-competent mice, will be discussed…

The role of drug transporters at the blood brain barrier

The role of drug transporters at the blood brain barrier

Biologics, Issue 1 2016 / 29 February 2016 / Jasminder Sahi and Yi Li, Sanofi R&D

The human brain is the most highly perfused organ in the body, being composed of over 100 billion capillaries with an average inter-capillary distance of 50μm and a length greater than 600km. This extensive network of blood vessels facilitates the delivery of nutrients and oxygen to the brain, while providing a physical, metabolic and immunologic barrier, the blood brain barrier (BBB), to protect it. The BBB comprises a very tight layer of capillary endothelial cells with elaborate tight junctions between adjacent cells that prevent most soluble materials from crossing, while allowing gases such as oxygen and carbon dioxide to diffuse through…

High Pressure Homogenisation & the next generation of drug delivery: Liposomes

High Pressure Homogenisation & the next generation of drug delivery: Liposomes

Supplier news / 24 February 2016 / Biopharma Group

Liposomes are valued delivery vehicles for potent and efficacious active pharmaceuticals…

Polyelectrolyte complexes as nanoparticulate drug delivery systems

Polyelectrolyte complexes as nanoparticulate drug delivery systems

Issue 3 2015, Manufacturing & Packaging / 3 July 2015 / Anita Umerska, University of Anger and Lidia Tajber, Trinity College Dublin

Polyelectrolyte complexes at the nanoscale (polyelectrolyte complex nanoparticles; PECNs) can be harnessed as drug delivery systems for a range of low molecular weight drugs as well as peptides and proteins. The mild method of manufacture of PECNs results in the protection of the loaded bioactive and the choice of polyions forming the carrier makes PECNs very flexible in the design of a range of medical and pharmaceutical applications. This paper presents the key characteristics of PECNs and developments in the area…

Particle Resizing

Particle characterisation in drug delivery

Issue 4 2014, Manufacturing & Packaging / 5 September 2014 / Driton Vllasaliu and Ishwar Singh, University of Lincoln

The use of materials in nano-scale dimensions is proving to be a promising approach to overcome drug delivery challenges. ‘Nanomedicine’ technologies are gradually achieving commercial success and reaching the clinic. Sub-micron nanocarriers have the potential to ferry the therapeutic to its site of action and in this process overcome the biological barriers and achieve targeted drug delivery, controlled or stimuli-responsive delivery and protect the therapeutic from biological milieus. Many different types of nanocarriers have been described, including polymeric nanoparticles (NPs), liposomes, solid lipid NPs, micelles, dendrimers and metal NPs among other systems (the terms ‘nanomedicine’, ‘NP’ and ‘nanocarriers’ are used herein to describe all nanosystems). Of particular interest are nanocarriers with the ability to act selectively and target cell internalisation processes, guiding the therapeutic into subcellular regions. NP features important in dictating their drug delivery performance, including targeted delivery and cellular trafficking, are their size, shape and surface characteristics such as surface charge, chemistry and the distribution of ligands…

Applications of MRI to controlled drug delivery devices

Issue 5 2012, Magnetic Resonance Imaging / 22 October 2012 / Mick Mantle, Department of Chemical Engineering & Biotechnology, University of Cambridge

Magnetic resonance imaging (MRI) is a technique that is traditionally used as a diagnostic clinical imaging tool. However, there are now an increasing number of non-medial applications where MRI has seen unrivalled success. One of those areas is in its application to pharmaceutical research. The aim of this article is to briefly outline the quantitative nature of MRI and how it has been used recently to quantify dissolution phenomena in controlled drug delivery tablets under pharmacopeial conditions.

In modern pharmacotherapy, the effectiveness of a therapeutic treatment does not rely solely on the efficacy of the active pharmaceutical ingredient (API), but is also dependent upon a suitable dosage form or drug delivery device being available. In many ways, it is the drug delivery device itself that ensures the active drug is available at the site of action for the correct time and duration with appropriate drug concentration1. Drug delivery systems can be broadly divided into two categories according to their mechanisms of drug release: immediate release and modified release. Immediate release dosage forms, such as traditional painkillers, are relatively simple systems and are designed to release APIs instantaneously, i.e. when a fast therapeutic action is required. Modified release dosage forms, which are generally more suited to disease treatment, are generally designed to provide targeted / tailored drug release characteristics and a detailed knowledge of the spatio-temporal behaviour of the API is extremely important.

Figure 1 Examples of chemical structures of antibodies for targeted pulmonary inhalation aerosol

Pulmonary inhalation aerosols for targeted antibiotics drug delivery

Ingredients, Issue 1 2011 / 16 February 2011 / Chun-Woong Park & Heidi M. Mansour, University of Kentucky, College of Pharmacy and Don Hayes Jr, University of Kentucky, College of Medicine

Targeted pulmonary drug delivery of antibiotics by inhalation aerosols can play significant roles in the treatment of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and in other pulmonary diseases where chronic airway infections exist. Direct administration to the lung as targeted pulmonary inhalation aerosol delivery is uniquely able to provide for high dose levels of drugs at the target site of action without systemic side effects. This review presents an overview of pulmonary inhalation aerosols, types of inhalation aerosols, aerosol formulation additives and present current research in the targeted pulmonary drug delivery of antibiotics for the treatment of pulmonary infections. Clinical trials of antibiotic inhalation aerosols are also discussed.

Who nose?

Issue 1 2005, Past issues / 7 March 2005 / Professor Richard Dalby and Yang Guo, University of Maryland School of Pharmacy, Julie Suman, Next Breath LLC

In 2003 worldwide sales of allergic rhinitis nasal sprays alone were valued at US$2.4B (IMS, Valois), up from 2002 worldwide sales of all over-the-counter (OTC) nasal sprays except steroids, estimated at US$820M (IMS, Valois). That’s a significant amount of drug administered via the nose every year (Figure 1). With a 2004 projection in the range of US$3.5-4B in sales, this is not a sector to be sniffed at.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...